drug 'Famvir' after the adoption of turns in the gastrointestinal tract to penciclovir.In turn, it penetrates into the cells infected with a virus, and goes into penciclovir phosphate which inhibits replication of viral DNA cells.
«Famvir" does not bring harm to the health of normal cells.Viruses do not get used to the drug and did not develop resistance to it.



Pharmacokinetics The drug is rapidly absorbed.Its bioavailability is 77%.O 'Famvir' primarily through the kidneys in the form of partially metabolize.

Indications

1. Treatment of genital herpes and its prevention.
2. Shingles.
3. Herpes simplex virus.
4. Herpes zoster in patients with lowered immunity.
5. cold sores.
6. cytomegalovirus infection.
7. Posthemorrhagic neuralgia.

Contraindications

«Famvir" do not take the age of 18, and
in cases of allergic reactions to constituents of the preparation.

Dosage

«Famvir 'is taken by mouth, do not chew and drink plenty of water.When shingles in people with normal immune systems, daily use of 500 mg 3 times.The course should last 1 week.In acute manifestations of herpes - 0.25 g 3 times a day.In some cases the possible single dose in a dosage of 0.75 g product.People with lowered immunity, with herpes zoster take 500 mg 3 times a day.Duration of treatment is 10 days.When cold sores is assigned to a single dose of 1500 mg.Patients with renal insufficiency should be taking the drug immediately after hemodialysis.

Overdose

As a rule, "Famvir" Accidental overdose is not clinically manifested.

Side effects

In most cases, the drug is well tolerated.Quite rarely possible nausea, dizziness, headaches and rash.Abdominal pain occurs in people with lowered immunity.The blood can be observed thrombocytopenia.Elderly patients developing a mental disorder in the form of confusion.On the part of the hepatobiliary system cholestatic jaundice and possible changes in the liver.Allergic reactions can manifest urticaria, angioedema, rash or itching.

Pregnancy and use of the drug

The drug should not be used during pregnancy becauseits safety has not yet been studied.Data on the allocation of penciclovir in breast milk is unknown.